Lipids to the Rescue in Pulmonary Fibrosis: Biosynthesis, Bioenergetics, or Epigenetics? (2024)

Lipids are essential to the homeostatic structure and function of cells, tissues, and organs. These essential roles of lipids include biosynthesis of biological membranes (permitting organelle compartmentalization), bioenergetics (as an efficient fuel source), and as potent signaling intermediates, both intracellular and extracellular; uniquely, in the lung, lipids are indispensable for surfactant synthesis by type 2 alveolar epithelial cells (AEC2s). AECs serve as facultative stem cells of the alveolus, and their dysfunction is now well recognized as a pivotal event in the pathogenesis of fibrotic lung diseases.

Over the past decade, although there has been growing recognition that lipid metabolism plays an important role in the pathogenesis of lung fibrosis, as reviewed in a recent perspective published online ahead of print in the Journal (1), there remains uncertainty regarding the precise molecular mechanisms (Figure 1). For example, although some studies support augmentation of lipid biosynthetic pathways as serving protective functions against lung fibrosis (2–5), others suggest that particular lipids may be harmful (6, 7). Such differences may be accounted for by differences in the specific lipid species involved, target cells, compartmentalized actions (at both organ-specific and subcellular levels), and experimental protocols.

In this issue of the Journal, Liang and colleagues (pp. 242–253) establish a correlation between lipid metabolism and AEC2 dysfunction in the context of experimental injury to a murine aging lung and in idiopathic pulmonary fibrosis (IPF) (8). Using flow cytometry, they isolated AEC2s from both IPF and healthy human donor lungs and subjected them to single-cell RNA sequencing analysis to explore genes associated with lipid metabolism. These studies revealed a downregulation of several genes related to fatty acid biosynthesis (e.g., CHKA, SCD, FASN, CAT, ACOXL, ELOVL6, LPCAT1, LPCAT3) in AEC2s of subjects with IPF compared with healthy human control subjects. Furthermore, genes associated with fatty acid β-oxidation (e.g., ACAT1, ACSL) were also downregulated in IPF AEC2 cells. In addition, genes involved in lipid uptake (e.g., CD36, SLC27A4, SLC27A5) and lipid storage (e.g., PLIN2, MGLL, HILPDA) were found to be downregulated in IPF AEC2s compared with healthy counterparts. Immunofluorescence experiments validated the findings of the single-cell RNA sequencing study, collectively indicating decreased lipid concentrations in the AEC2s of subjects with IPF.

To corroborate their findings in an animal model, the researchers studied an aging mouse model with bleomycin-induced lung injury and three-dimensional (3D) organoids using AEC2s and lung fibroblasts. These invivo and ex vivo models consistently demonstrated a decrease in AEC2 lipid content in aged, injured mice, as observed in IPF AECs. Interestingly, 3D organoid models of human and mouse AECs supplemented with a lower concentration (2%) of exogenous lipids promoted renewal in young mice but not in older ones. However, a higher lipid concentration (4%) facilitated renewal in both young and aged AEC2 organoids. This enhanced regenerative capacity was evidenced by increased colony size, AEC2 proliferation rate, elevated expression of AEC1 marker genes (AGER, AQP5, T1α), and AEC2-related surfactant proteins in lipid-treated organoids compared with control animals. Furthermore, the researchers used a PPARγ agonist (rosiglitazone) and antagonist (GW9662) in the human organoid model to demonstrate that rosiglitazone augmented colony formation of AEC2s from healthy lungs, whereas GW9662 decreased it. Notably, treatment with 10 μM rosiglitazone significantly increased colony formation of AEC2s from IPF lungs compared with control lungs.

The studies by Liang and colleagues (8) advance the concept that abnormal lipid metabolism contributes to AEC2 dysfunction, a hallmark of IPF. An exciting aspect of this work is the demonstration that regenerative capacity of aged AEC2s in the 3D organoid model can be rejuvenated with lipid supplementation or with PPARγ agonists. Although subpopulations of fibroblasts are known to support the AEC2 stem cell niche (9), the role of lipids in their interactions may be complex. For example, a recent study showed that exosomes from IPF lungs carry micro-RNAs that inhibit the de novo fatty acid synthesis pathway in AEC2s (4, 10). In addition, AEC2-supporting fibroblasts have been known to transfer lipids to adjacent AEC2s to support surfactant production (11, 12), and the aging of the mesenchyme itself may contribute to AEC2 dysfunction (10, 13). Thus, defects in cell autonomous lipid metabolism or in niche-supporting cells such as fibroblasts and macrophages (14) may cooperatively account for the AEC2 dysfunction in IPF.

Future investigations must clarify whether (and how) specific variations in lipid species and their compartmentalized actions alter AEC2 function. The metabolic flux of lipids controlled by dynamic changes in lipid biosynthesis, storage, transport, and consumption (via fatty acid oxidation) in AEC2s and their niche-supporting cells remains unclear. Although the “rescue” studies with lipid supplementation promises to open up new therapeutic strategies, it would be important to decipher if the mechanistic basis for more robust regenerative responses is due to lipid support of membrane biosynthesis (critical for proliferating cells), cellular bioenergetics (which wanes with aging), or epigenetic programs (regulated by lipid signaling intermediates). It could not simply be due to more surfactant synthesis, could it?

Footnotes

References